Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystic Fibrosis | 25 | 2021 | 256 | 1.660 |
Why?
|
Respiratory Syncytial Virus Infections | 6 | 2007 | 344 | 0.510 |
Why?
|
Pseudomonas Infections | 7 | 2013 | 114 | 0.470 |
Why?
|
Pseudomonas aeruginosa | 6 | 2013 | 164 | 0.330 |
Why?
|
HN Protein | 2 | 1998 | 18 | 0.270 |
Why?
|
Respiratory Syncytial Viruses | 6 | 2003 | 147 | 0.270 |
Why?
|
Viral Proteins | 2 | 1998 | 347 | 0.240 |
Why?
|
Respiratory Function Tests | 8 | 2013 | 198 | 0.230 |
Why?
|
Tobramycin | 3 | 2011 | 23 | 0.220 |
Why?
|
Viral Vaccines | 3 | 2003 | 337 | 0.180 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2021 | 46 | 0.180 |
Why?
|
Respiration | 1 | 1999 | 119 | 0.150 |
Why?
|
Adenoviruses, Human | 1 | 1998 | 81 | 0.150 |
Why?
|
Adenovirus Infections, Human | 1 | 1998 | 50 | 0.150 |
Why?
|
Antibodies, Viral | 3 | 1999 | 1155 | 0.140 |
Why?
|
Respiratory Tract Infections | 4 | 2007 | 273 | 0.140 |
Why?
|
Viral Fusion Proteins | 1 | 1998 | 76 | 0.140 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2014 | 43 | 0.140 |
Why?
|
Infant | 20 | 2013 | 12462 | 0.130 |
Why?
|
Child, Preschool | 19 | 2012 | 13984 | 0.120 |
Why?
|
Aminophenols | 1 | 2014 | 7 | 0.120 |
Why?
|
Cough | 2 | 2013 | 91 | 0.110 |
Why?
|
Quinolones | 1 | 2014 | 54 | 0.110 |
Why?
|
Ribavirin | 1 | 1994 | 79 | 0.110 |
Why?
|
Vaccination | 2 | 1998 | 961 | 0.110 |
Why?
|
Ion Channel Gating | 1 | 2014 | 122 | 0.110 |
Why?
|
Anti-Bacterial Agents | 3 | 2011 | 2425 | 0.090 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2013 | 133 | 0.090 |
Why?
|
Ciprofloxacin | 1 | 2011 | 66 | 0.090 |
Why?
|
Sleep | 1 | 1992 | 344 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2011 | 1096 | 0.080 |
Why?
|
Functional Residual Capacity | 4 | 2013 | 14 | 0.080 |
Why?
|
Oxygen | 1 | 1992 | 555 | 0.080 |
Why?
|
Anti-Infective Agents | 1 | 2011 | 265 | 0.080 |
Why?
|
Vaccines, Synthetic | 2 | 2003 | 316 | 0.080 |
Why?
|
Lung | 3 | 2013 | 1497 | 0.070 |
Why?
|
Metaproterenol | 1 | 1988 | 1 | 0.070 |
Why?
|
Male | 22 | 2014 | 61439 | 0.070 |
Why?
|
Pulmonary Ventilation | 1 | 1988 | 28 | 0.070 |
Why?
|
Forced Expiratory Volume | 3 | 2014 | 171 | 0.070 |
Why?
|
Female | 23 | 2014 | 66721 | 0.070 |
Why?
|
Humans | 32 | 2021 | 125037 | 0.070 |
Why?
|
Plethysmography | 3 | 2011 | 35 | 0.070 |
Why?
|
Paramyxoviridae Infections | 1 | 2007 | 47 | 0.070 |
Why?
|
Metapneumovirus | 1 | 2007 | 51 | 0.070 |
Why?
|
Prospective Studies | 7 | 2012 | 6153 | 0.070 |
Why?
|
Oropharynx | 3 | 2002 | 34 | 0.070 |
Why?
|
Viral Envelope Proteins | 2 | 1998 | 152 | 0.060 |
Why?
|
Longitudinal Studies | 4 | 2013 | 1328 | 0.060 |
Why?
|
Respiratory Tract Diseases | 2 | 2001 | 75 | 0.060 |
Why?
|
Child | 9 | 2021 | 24356 | 0.060 |
Why?
|
Maximal Expiratory Flow-Volume Curves | 1 | 2004 | 1 | 0.060 |
Why?
|
Maximal Expiratory Flow Rate | 1 | 2004 | 2 | 0.060 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2007 | 206 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2014 | 1638 | 0.050 |
Why?
|
Oligopeptides | 1 | 2003 | 118 | 0.050 |
Why?
|
Placebos | 2 | 2011 | 241 | 0.050 |
Why?
|
Administration, Inhalation | 3 | 2011 | 180 | 0.050 |
Why?
|
Genome, Bacterial | 1 | 2003 | 186 | 0.050 |
Why?
|
Carrier State | 1 | 2002 | 76 | 0.050 |
Why?
|
Oscillometry | 2 | 2011 | 15 | 0.050 |
Why?
|
Clofazimine | 1 | 2021 | 7 | 0.050 |
Why?
|
Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.050 |
Why?
|
Spirometry | 2 | 2011 | 73 | 0.050 |
Why?
|
Regression Analysis | 2 | 2004 | 779 | 0.050 |
Why?
|
Sensitivity and Specificity | 4 | 2011 | 2054 | 0.050 |
Why?
|
Forced Expiratory Flow Rates | 1 | 2001 | 7 | 0.050 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2001 | 36 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2002 | 150 | 0.040 |
Why?
|
Mutation | 1 | 2014 | 5846 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2013 | 2889 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 1992 | 1821 | 0.040 |
Why?
|
Incidence | 3 | 2013 | 3137 | 0.040 |
Why?
|
Scimitar Syndrome | 1 | 2001 | 52 | 0.040 |
Why?
|
Intestinal Obstruction | 2 | 2000 | 93 | 0.040 |
Why?
|
Ileostomy | 1 | 2000 | 31 | 0.040 |
Why?
|
HIV Infections | 2 | 2001 | 1897 | 0.040 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2001 | 240 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2011 | 762 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2002 | 730 | 0.040 |
Why?
|
Neutralization Tests | 1 | 1998 | 236 | 0.040 |
Why?
|
Lung Compliance | 2 | 1988 | 19 | 0.040 |
Why?
|
Bacterial Infections | 1 | 1999 | 307 | 0.030 |
Why?
|
Genotype | 3 | 2013 | 2561 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2001 | 454 | 0.030 |
Why?
|
Cohort Studies | 4 | 2011 | 4812 | 0.030 |
Why?
|
Environment | 1 | 1996 | 145 | 0.030 |
Why?
|
Air Microbiology | 1 | 1994 | 11 | 0.030 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 1996 | 173 | 0.030 |
Why?
|
Aerosols | 1 | 1994 | 65 | 0.030 |
Why?
|
Genetic Vectors | 1 | 1998 | 937 | 0.030 |
Why?
|
Oxygen Inhalation Therapy | 1 | 1994 | 90 | 0.030 |
Why?
|
Genetic Therapy | 1 | 1998 | 687 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2014 | 315 | 0.030 |
Why?
|
Respirovirus Infections | 1 | 1993 | 19 | 0.030 |
Why?
|
Molecular Typing | 1 | 2013 | 34 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2013 | 151 | 0.020 |
Why?
|
Infant, Newborn | 4 | 2001 | 8196 | 0.020 |
Why?
|
Molecular Epidemiology | 1 | 2013 | 155 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2002 | 2906 | 0.020 |
Why?
|
Cyanosis | 1 | 1992 | 42 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 398 | 0.020 |
Why?
|
Prevalence | 1 | 1998 | 2452 | 0.020 |
Why?
|
Infection Control | 1 | 2013 | 155 | 0.020 |
Why?
|
Oximetry | 1 | 1992 | 168 | 0.020 |
Why?
|
Reference Values | 2 | 2004 | 715 | 0.020 |
Why?
|
Tobacco Smoke Pollution | 1 | 2011 | 76 | 0.020 |
Why?
|
Hypoxia | 1 | 1992 | 248 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2011 | 12382 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2011 | 3299 | 0.020 |
Why?
|
Bronchoscopy | 2 | 2001 | 152 | 0.020 |
Why?
|
Staphylococcus aureus | 1 | 2013 | 460 | 0.020 |
Why?
|
Administration, Oral | 1 | 2011 | 684 | 0.020 |
Why?
|
Body Mass Index | 1 | 2014 | 1563 | 0.020 |
Why?
|
Adult | 3 | 2014 | 29625 | 0.020 |
Why?
|
Staphylococcal Infections | 1 | 2013 | 561 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2013 | 760 | 0.020 |
Why?
|
Lung Volume Measurements | 1 | 1988 | 75 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 1356 | 0.020 |
Why?
|
Solutions | 1 | 2007 | 65 | 0.020 |
Why?
|
Respiratory Sounds | 1 | 1988 | 68 | 0.020 |
Why?
|
United States | 2 | 2013 | 10909 | 0.020 |
Why?
|
Nasopharynx | 1 | 2007 | 79 | 0.020 |
Why?
|
Morbidity | 1 | 2007 | 248 | 0.020 |
Why?
|
Meconium | 2 | 2000 | 11 | 0.020 |
Why?
|
Age Factors | 2 | 2002 | 2817 | 0.020 |
Why?
|
Pyocins | 1 | 2003 | 1 | 0.010 |
Why?
|
Pigments, Biological | 1 | 2003 | 7 | 0.010 |
Why?
|
Melanins | 1 | 2003 | 18 | 0.010 |
Why?
|
Databases as Topic | 1 | 2004 | 72 | 0.010 |
Why?
|
Base Composition | 1 | 2003 | 71 | 0.010 |
Why?
|
Pseudomonas Phages | 1 | 2003 | 9 | 0.010 |
Why?
|
Risk Factors | 2 | 2013 | 10282 | 0.010 |
Why?
|
Gene Transfer, Horizontal | 1 | 2003 | 43 | 0.010 |
Why?
|
RNA, Transfer | 1 | 2003 | 72 | 0.010 |
Why?
|
Adolescent | 2 | 2014 | 19330 | 0.010 |
Why?
|
Immunization Schedule | 1 | 2003 | 102 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 3424 | 0.010 |
Why?
|
Audiometry | 1 | 2002 | 21 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2012 | 5169 | 0.010 |
Why?
|
Hearing Disorders | 1 | 2002 | 27 | 0.010 |
Why?
|
Sputum | 1 | 2002 | 106 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2003 | 271 | 0.010 |
Why?
|
Safety | 1 | 2002 | 217 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2003 | 478 | 0.010 |
Why?
|
Seasons | 1 | 2003 | 312 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2003 | 524 | 0.010 |
Why?
|
Infant Welfare | 1 | 2001 | 28 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2002 | 172 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 2003 | 383 | 0.010 |
Why?
|
Creatinine | 1 | 2002 | 390 | 0.010 |
Why?
|
Aorta, Abdominal | 1 | 2001 | 126 | 0.010 |
Why?
|
Vena Cava, Inferior | 1 | 2001 | 103 | 0.010 |
Why?
|
Young Adult | 1 | 2014 | 9045 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2003 | 1016 | 0.010 |
Why?
|
Probability | 1 | 2001 | 321 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2003 | 769 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2001 | 243 | 0.010 |
Why?
|
Pulmonary Veins | 1 | 2001 | 161 | 0.010 |
Why?
|
Patient Selection | 1 | 2003 | 699 | 0.010 |
Why?
|
Linear Models | 1 | 2001 | 680 | 0.010 |
Why?
|
Radiography | 1 | 2001 | 820 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2001 | 1020 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2001 | 682 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2000 | 389 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2002 | 479 | 0.010 |
Why?
|
Hospitalization | 1 | 2007 | 1779 | 0.010 |
Why?
|
Pregnancy | 2 | 2001 | 7192 | 0.010 |
Why?
|
Pulmonary Artery | 1 | 2001 | 442 | 0.010 |
Why?
|
Microbial Sensitivity Tests | 1 | 2000 | 796 | 0.010 |
Why?
|
HIV-1 | 1 | 2001 | 465 | 0.010 |
Why?
|
Cardiac Catheterization | 1 | 2001 | 634 | 0.010 |
Why?
|
Sex Factors | 1 | 2001 | 1287 | 0.010 |
Why?
|
Genetic Variation | 1 | 2003 | 1501 | 0.010 |
Why?
|
Time Factors | 1 | 2007 | 6327 | 0.010 |
Why?
|
Ultrasonography | 1 | 2001 | 940 | 0.010 |
Why?
|
Cytokines | 1 | 2001 | 1285 | 0.010 |
Why?
|
Middle Aged | 1 | 2014 | 26922 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 1999 | 2168 | 0.010 |
Why?
|
Sheep | 1 | 1993 | 220 | 0.010 |
Why?
|
Phenotype | 1 | 2000 | 4259 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2001 | 3570 | 0.010 |
Why?
|
Animals, Newborn | 1 | 1993 | 1016 | 0.000 |
Why?
|
Models, Biological | 1 | 1993 | 1461 | 0.000 |
Why?
|
Failure to Thrive | 1 | 1988 | 90 | 0.000 |
Why?
|
Animals | 1 | 1993 | 34206 | 0.000 |
Why?
|